ATE463252T1 - Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf - Google Patents

Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf

Info

Publication number
ATE463252T1
ATE463252T1 AT01968180T AT01968180T ATE463252T1 AT E463252 T1 ATE463252 T1 AT E463252T1 AT 01968180 T AT01968180 T AT 01968180T AT 01968180 T AT01968180 T AT 01968180T AT E463252 T1 ATE463252 T1 AT E463252T1
Authority
AT
Austria
Prior art keywords
igf
treating
nervous system
central nervous
application
Prior art date
Application number
AT01968180T
Other languages
English (en)
Inventor
Douglas Ishii
Original Assignee
Aurogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22857995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE463252(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aurogen Inc filed Critical Aurogen Inc
Application granted granted Critical
Publication of ATE463252T1 publication Critical patent/ATE463252T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01968180T 2000-08-29 2001-08-28 Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf ATE463252T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22863300P 2000-08-29 2000-08-29
PCT/US2001/026750 WO2002017951A1 (en) 2000-08-29 2001-08-28 Method for treating the central nervous system by administration of igf structural analogs

Publications (1)

Publication Number Publication Date
ATE463252T1 true ATE463252T1 (de) 2010-04-15

Family

ID=22857995

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01968180T ATE463252T1 (de) 2000-08-29 2001-08-28 Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf

Country Status (10)

Country Link
US (1) US20060105946A9 (de)
EP (1) EP1313499B1 (de)
JP (2) JP5111716B2 (de)
CN (1) CN1469752A (de)
AT (1) ATE463252T1 (de)
AU (2) AU8844301A (de)
CA (1) CA2419561A1 (de)
DE (1) DE60141759D1 (de)
ES (1) ES2346185T3 (de)
WO (1) WO2002017951A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009988B1 (ru) * 2003-07-29 2008-04-28 Арес Трейдинг С.А. Применение человеческого гормона роста при множественной системной атрофии
JP4305547B2 (ja) * 2006-10-27 2009-07-29 エプソンイメージングデバイス株式会社 実装構造体、電気光学装置、電子機器及び実装構造体の製造方法
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CA2800173C (en) 2010-05-21 2019-05-14 Ulrik Nielsen Bi-specific fusion proteins
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
CN108114271B (zh) * 2016-11-29 2021-07-02 中国科学院上海营养与健康研究所 含胰岛素样生长因子-2的药物组合物及其应用
ES2927133B2 (es) * 2021-04-28 2023-12-29 Univ Malaga Tratamiento para la enfermedad de Parkinson

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898856A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
CA2074166C (en) * 1990-02-13 2003-11-25 Francis J. Ballard Method for treating intestinal diseases
US5679771A (en) * 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
JP3034032B2 (ja) * 1990-02-13 2000-04-17 グロペップ プロプライエタリー リミテッド 腸疾患用薬剤
NZ234439A (en) 1990-07-10 1997-08-22 Pharmacia & Upjohn Ab Use of igf-1 to reduce fetal growth retardation in non human mammals
DK0597033T3 (da) * 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
CA2135306A1 (en) * 1992-05-08 1993-11-25 Bradford A. Jameson Igf-1 analogs
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone

Also Published As

Publication number Publication date
EP1313499A4 (de) 2004-05-26
JP2004513884A (ja) 2004-05-13
AU8844301A (en) 2002-03-13
US20060105946A9 (en) 2006-05-18
ES2346185T3 (es) 2010-10-13
JP2012197290A (ja) 2012-10-18
EP1313499A1 (de) 2003-05-28
AU2001288443B2 (en) 2007-06-07
CA2419561A1 (en) 2002-03-07
DE60141759D1 (de) 2010-05-20
CN1469752A (zh) 2004-01-21
JP5111716B2 (ja) 2013-01-09
US20050101527A1 (en) 2005-05-12
WO2002017951A1 (en) 2002-03-07
EP1313499B1 (de) 2010-04-07

Similar Documents

Publication Publication Date Title
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE389411T1 (de) Strontium verbindung zur behandlung von sub- dermalem weichteilschmerz
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
WO2002000227A8 (en) Use of lanthanum compounds for the treatment of bone diseases
ATE328605T1 (de) Verwendung von insulin zur behandlung von knorpelkrankheiten
BR0014710A (pt) Métodos para o tratamento de dor
ATE252078T1 (de) Carbonsäuren und carbonsäureisostere von n- heterocyclischen verbindungen
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
ATE463252T1 (de) Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
ATE409028T1 (de) Arzneien zur behandlung von nervenerkrankungen
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
DE60213116D1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
BR9912609A (pt) Métodos de uso de um análogo de somatostatina
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
SE0100873D0 (sv) Method of treatment
DE60108775T8 (de) Methode zur behandlung von schlaganfall
DE59309063D1 (de) Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
ATE374021T1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post- chirurgischen schmerzbehandlung
DE60233353D1 (de) Verfahren zur behandlung von halitose
ATE304862T1 (de) Verwendung einer zusammensetzung enthaltend zumindest ein gnrh-analoges zur behandlung von zwangsneurotischen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties